newsfilter
← Latest News
GlobeNewswire·

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced